Form 4: Director Timothy C. Barabe Increases Stake in Cartesian Therapeutics

Director Timothy C. Barabe recently purchased 7,500 shares of Cartesian Therapeutics (RNAC) at $12.70 per share, increasing his total holdings.

Summary

• On August 12, 2024, Timothy C. Barabe, a director of Cartesian Therapeutics, Inc. (RNAC), acquired 7,500 shares of common stock at a price of $12.70 per share.
• Following this transaction, Barabe directly owns 21,766 shares of Cartesian Therapeutics.
• Barabe also holds a stock option to purchase 7,600 shares of common stock at an exercise price of $19.656, vesting in 36 equal monthly installments and fully vested by January 1, 2034.
• The reported securities amounts have been adjusted to reflect a 1-for-30 reverse stock split that occurred on April 4, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates a director's recent purchase of company stock.

Stakeholder Impact

• The director's stock purchase could positively influence shareholder sentiment.

Key Dates